

*The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**上海復旦張江生物醫藥股份有限公司**  
**Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\***  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code:1349)**

**APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR**

The first meeting of the employee representatives of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (the “Company”) in 2016 (the “Meeting”) was held on 22 February 2016 at No. 308 Cailun Road, Zhangjiang Hi-tech Park, Pudong New Area, Shanghai, the People’s Republic of China, at which the resolution relating to the supplementary election of employee representative supervisor of the fifth session of the supervisory committee was considered and approved. As elected at the Meeting, Mr. Wang Luochun (“**Mr. Wang**”) has been appointed as an employee representative supervisor of the fifth session of the supervisory committee of the Company.

The biographical details of Mr. Wang required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) are set out as follows:

**Mr. Wang Luochun**, aged 46, has been appointed as an employee representative supervisor. He is the manager of biopharmaceutical drug research and development department of the Company. He joined the Company in March 1997 and has been engaged in the research and development for biopharmaceutical drugs. He graduated from Fudan University with a bachelor’s degree in Biology in July 1992.

Mr. Wang has entered into a service contract with the Company. The office term of Mr. Wang commenced from 22 February 2016 until the date of the annual general meeting of

the Company to be held around June 2017 (except for re-election). The Company is not required to pay any supervisor's remuneration or emolument to Mr. Wang.

Mr. Wang indirectly holds 1,170,000 domestic shares of the Company through Shanghai Zhiyuan Investment Center LP(上海志淵投資中心(有限合夥)) due to his participation in the restricted share scheme implemented by the Company in 2013, representing approximately 0.13% of the total issued share capital of the Company.

As at the date of this announcement, saved as disclosed above, Mr. Wang does not (i) hold any directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (ii) hold any position with the Company or its subsidiaries; (iii) have any interest, deemed interest or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance; or (iv) have any relationship with other current directors, senior management, substantial shareholders of the Company.

There is no information required to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules in relation to Mr. Wang and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

By order of the board

**Wang Hai Bo**

*Chairman*

As at the date thereof, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Ms. Ke Ying (Non-executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent non-executive Director)

Mr. Lam Yiu Kin (Independent non-executive Director)

Mr. Xu Qing (Independent non-executive Director)

Shanghai, the PRC

23 February 2016

*\* For identification purpose only*